drugset / Trial / NCT01693419
S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
Phase 2
Completed
37 enrolled
Hallym University Medical Center
Jeil Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will conduct a phase II study of gemcitabine, erlotinib, and S-1 as first-line chemotherapy in patients with advanced pancreatic cancer and evaluate the EGFR expression, KRAS mutation, and BRAF mutation as predictive or prognostic markers
Timeline
- Start
- 2011-08
- Primary completion
- 2016-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 100 mg | Oral |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 60 mg/m2 | Oral |